Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD388 Subcutaneous Administration in Healthy Japanese Subjects
Conditions
Interventions
CD388 Injection
Saline placebo
Locations
1
United States
Altasciences Clinical Los Angeles, Inc.
Cypress, California, United States
Start Date
October 18, 2022
Primary Completion Date
July 14, 2023
Completion Date
July 14, 2023
Last Updated
October 1, 2024
NCT06716502
NCT06290258
NCT07310264
NCT00090662
NCT07483606
NCT06342713
Lead Sponsor
Cidara Therapeutics Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions